^
Association details:
| Biomarker: | PDGFRA exon 18 mutation |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | Qinlock (ripretinib) (c-KIT inhibitor, FLT3 inhibitor, PDGFR α inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
03/13/2023
Excerpt:
Gastrointestinal Stromal Tumors….Ripretinib is also an option for GIST with PDGFRA exon 18 mutations that are insensitive to imatinib and were previously treated with both avapritinib and dasatinib.
